Vasomune Therapeutics is a Toronto-based biotechnology company developing first in class therapies to target a range of acute vascular complications. These represent a significant >$5B market opportunity to target “vascular leak” complications related to infection, cardiac surgery, trauma and transplants. The company’s lead compound is Vasculotide, a Tie2 receptor agonist that is being developed for the treatment of Acute Lung Injury (ALI)/Acute Respiratory Distress Syndrome (ARDS). Vasomune has raised $3 million in seed financing which will be used to support manufacturing, pharmacology, toxicology and define a clear path to the clinic. Vasomune is seeking a co-development partnership with a large, multinational pharmaceutical company to fund its lead drug, Vasculotide, into clinical trials.